Trial · NCT05742763
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
NCT05742763, Phase 1, Phase 2, Withdrawn, QC Kinetix LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis. Trials, record NCT05742763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05742763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
- NCT number
- NCT05742763
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- QC Kinetix LLC
- Conditions
- Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
- Interventions
- Ibuprofen and PRP, Acetaminophen and PRP, Placebo and PRP
- First posted
- 2023-02-24
- Last updated
- 2024-10-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | VAS pain scores after combination interventions of blinded medication therapy and a series of 3 PRP injections. | Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12. | The investigators will obtain standardized and validated pain scores. The first is the VAS. The scale is 0-10. 0 is "no pain" and 10 is "unbearable pain". |
| Primary | WOMAC pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections. | Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12. | The investigators will obtain standardized and validated pain scores. The second is the WOMAC. The scale is 0-96. 0 is "no pain and no loss of function" and 96 is "unbearable pain and complete loss of function". |
| Primary | KOOS pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections. | Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12. | The investigators will obtain standardized and validated pain scores. The third is the KOOS. The scale is 0-100. 0 is "no pain and no loss of function" and 100 is "unbearable pain and complete loss of function". |
| Primary | IKDC pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections. | Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12. | The investigators will obtain standardized and validated pain scores. The fourth is the IKDC. The scale is 0-100. 100 is "no pain and no loss of function" and 0 is "unbearable pain and complete loss of function". |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05742763
GET https://conductscience.org/api/trials/v1/NCT05742763/registered